Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim reported positive results from a similar phase 3 trial assessing its PDE4B ...

For days, she dealt with the nagging pain. One day, she and her daughter went to the mall, and Caprario decided to run up and down the stairs to try and relieve the discomfort. On other days, she ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

Blood clots form in response to signals from the lungs of cancer patients—not from other organ sites, as previously ...

Lung ultrasound (LUS) may be an effective screening tool for interstitial lung disease in patients with asymptomatic rheumatoid arthritis.

The median length of survival for individuals with ILD who completed pulmonary rehabilitation was 6.1 years vs 4.7 years in the control group. Pulmonary rehabilitation (PR) may improve survival at 5 ...

"We are thrilled to welcome Dr. Kokoszynska to our team," said Patrick A. Taylor, York Hospital president and CEO. "Her ...

Prospective study on abemaciclib-induced interstitial lung disease in metastatic breast cancer reveals a 7.4% incidence rate.

Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...